Clinical trials: Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis, Juvenile Laryngeal Papilloma
Avelumab for People With Recurrent Respiratory Papillomatosis
Background: Recurrent respiratory papillomatosis (RRP) is a rare disease caused by human papillomavirus. It can cause voice changes, airway compromise, pulmonary lesions, and cancers.
- Conditions
- Recurrent Respiratory Papillomatosis, Juvenile Laryngeal Papilloma, Laryngeal Papilloma, Recurrent, Respiratory Papillomatosis
- Trial name
- NCT02859454
- Testing
- Avelumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Laryngeal Papillomatosis, Human Papilloma Virus
Human Papillomatosis Genotyping of Children in Thailand
The purpose of the present study was to identify risk factors for more severe juvenile Recurrent Respiratory Papillomatosis (RRP) through prospective evaluation of a pediatric population in Thailand by the employing a protocol…
- Trial name
- NCT01304966
- Testing
- biopsy
- Where
- 2 sites in Thailand
- Volunteers
- 15 people
- Sponsor
- Queen Sirikit National Institute of Child Health
Recurrent Respiratory Papillomatosis
Use of Cidofovir for Recurrent Respiratory Papillomatosis
Recurrent respiratory papillomatosis (RRP) is the most common benign neoplasm of the larynx in the pediatric population. The impact of the disease on patients and families can be tremendous due to the need for frequent treatment.
- Trial name
- NCT00205374
- Testing
- Cidofovir
- Volunteers
- 19 people
- Sponsor
- University of Wisconsin, Madison
Lung Diseases, Obstructive, Sarcoidosis
Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")
The purpose of this study is to evaluate the safety, effectiveness, and side effects of the CryoSpray AblationTM System (CryoSpray AblationTM, "CSA" or "cryospray therapy") to treat benign airway disease in the lung using liquid…
- Conditions
- Lung Diseases, Obstructive, Sarcoidosis, Wegener's Granulomatosis, Rhinoscleroma
- Trial name
- ICEtheBAD (NCT00747461)
- Testing
- CryoSpray Ablation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- CSA Medical, Inc.
Recurrent Respiratory Papillomatosis, Respiratory Papillomatosis
M7824 in People With Recurrent Respiratory Papillomatosis
Background: Programmed cell death protein 1 (PD-L1) is a protein on the surface of cells. It regulates if a cell can be killed by immune system cells.
- Conditions
- Recurrent Respiratory Papillomatosis, Respiratory Papillomatosis, Laryngeal Papilloma, Recurrent, Human Papilloma Virus
- Trial name
- NCT03707587
- Testing
- M7824
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Respiratory Papillomatosis
Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)
This phase I single center open labeled study is planned to assess the safety and tolerability of bevacizumab for treating patients with bilateral Recurrent Respiratory Papillomatosis (RRP).
- Trial name
- NCT01020747
- Testing
- Avastin® (bevacizumab), Saline
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Recurrent Respiratory Papillomatosis
Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis
This is a randomized double blind controlled study to determine if celebrex (celecoxib), a selective COX-2 inhibitor, can decrease the rate of recurrence in adult and pediatric patients with recurrent respiratory papillomatosis.
- Trial name
- NCT00571701
- Testing
- celebrex (celecoxib)
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Northwell Health
Respiratory Papillomatosis
INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)
This is a Phase 1/2 open-label, multicenter trial to evaluate the safety, tolerability, immunogenicity, and efficacy of INO-3107 in participants with human papilloma virus type 6 (HPV-6) and/or type 11 (HPV-11)-associated…
- Trial name
- NCT04398433
- Testing
- INO-3107, CELLECTRA® 2000
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Inovio Pharmaceuticals
Recurrent Respiratory Papillomatosis
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
This research study is evaluating an immune modulatory agent as a possible treatment for patients with Recurrent Respiratory Papillomatosis (RRP) with significant disease involving the larynx, trachea, and/or lungs.
- Trial name
- NCT02632344
- Testing
- Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital